The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

July 27, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors.

You Might Also Like
  • U.S. Senator Launches Probe into 5 Top Opioid Drugmakers
  • U.S. Senator Reveals Results of Opioid Inquiry into Insys
  • U.S. State Attorneys General Probe Opioid Drug Companies

The top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to report and investigate the diversion of drugs for illicit use.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigation comes at a time when lawmakers and regulators take steps to combat the epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according to the U.S. Centers for Disease Control and Prevention.

McCaskill requested documents and information from opioid manufacturers Mallinckrodt Plc, Endo International Plc, Teva Pharmaceutical and Allergan Plc.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In March, McCaskill asked Johnson and Johnson, Mylan NV, Purdue Pharma, Insys Therapeutics Inc and Depomed Inc for internal estimates of the risk of abuse, addiction and overdose of opioids.

The senator also sent a request to McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, focusing on their distribution of opioid products.

McCaskill also requested for information on compensation provided that is in any way derived from revenue or profitability targets for sales of opioid products.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We appreciate Senator McCaskill’s inquiry and look forward to thoughtfully answering her questions,” McKesson spokeswoman said in an email, adding that there was no link between the sale of controlled substances and incentive compensation for the company’s executives.

AmerisourceBergen said it would respond to the letter from the Senator, adding it provides daily reports to the regulators about the quantity, type and receiving pharmacy of every single order of controlled substances it distributes.

Endo said it received the letter and would provide the Senator with the requested information.

Cardinal Health, Mallinckrodt, Allergan and Teva did not immediately respond to request for comments.

 

Filed Under: Drug Updates, Legal Tagged With: Allergan Plc., Endo International Plc, Mallinckrodt Plc, opioid crisis, Opioid probe, Teva Pharmaceuticals, U.S. Democratic Senator Claire McCaskill

You Might Also Like:
  • U.S. Senator Launches Probe into 5 Top Opioid Drugmakers
  • U.S. Senator Reveals Results of Opioid Inquiry into Insys
  • U.S. State Attorneys General Probe Opioid Drug Companies
  • Delaware Sues Opioid Manufacturers, Distributors Over Epidemic

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.